This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment
GeroScience Open Access 12 December 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Malumbres M, Barbacid M . To cycle or not to cycle: a critical decision in cancer. Nat Cancer Rev 2001; 1: 222–231.
Lee MH, Yang HY . Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 2001; 58: 1907–1922.
Chim CS, Liang R, Kwong YL . Gene promoter hypermethylation in hematologic malignancies. Hematol Oncol 2002; 20: 167–176.
Chim CS, Fung TK, Cheung J, Liang R, Kwong YL . SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 2004; 103: 4630–4635.
Chim CS, Fung TK, Liang R . Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia 2003; 17: 2533–2535.
Ying J, Srivastava G, Gao Z, Zhang X, Murray P, Ambinder R et al. Promoter hypermethylation of the cyclin-dependent kinase inhibitor (CDKI) gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas. Blood 2004; 103: 743–746.
Shiohara M, el-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781–3784.
Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995; 55: 2266–2269.
Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153–1160.
Li Y, Nagai H, Ohno T, Yuge M, Hatano S, Ito E et al. Aberrant DNA methylation of p57 (KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 2002; 100: 2572–2577.
Tetsu O, McCormick F . Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3: 233–245.
Acknowledgements
We thank Dr Andrew Zannettino, Myeloma and Mesenchymal Research Laboratory, Division of Haematology, Institute of Medical and Veterinary Science, and Hanson Institute, Adelaide, Australia, for the six cell lines. We also thank Miss YY Chan and her team for the excellent nursing care of the patients.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Chim, C., Liang, R., Fung, T. et al. Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myeloma. Leukemia 19, 2352–2355 (2005). https://doi.org/10.1038/sj.leu.2403904
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403904
This article is cited by
-
Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment
GeroScience (2023)
-
The mechanistic role of epigenetic in multiple myeloma
Comparative Clinical Pathology (2016)
-
piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma
Leukemia (2015)
-
Methylation of miR124a-1, miR124a-2, and miR124a-3 in Hodgkin lymphoma
Tumor Biology (2015)
-
Promoter hypermethylation of p73 and p53 genes in cervical cancer patients among north Indian population
Molecular Biology Reports (2012)